{"filing":{"accession_number":"0001575872-26-000538","cik":"0001135951","ticker":"RDY","company_name":"DR REDDYS LABORATORIES LTD","form":"6-K","filing_date":"2026-07-29","report_date":"2026-07-29","primary_document":"rdy0932_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1135951/000157587226000538/rdy0932_6k.htm"},"events":[{"id":21533,"run_id":19423,"accession_number":"0001575872-26-000538","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Dr. Reddy's discloses completion of a USFDA Pre-Approval Inspection (PAI) and GMP inspection at its FTO-SEZ Process Unit-02 in Srikakulam, with issuance of a Form 483 containing three observations. This is a regulatory inspection outcome at a manufacturing facility that would affect investor assessment of the company's regulatory compliance status and ability to obtain or maintain FDA approvals for products manufactured at this unit. While not a discrete operational event like a contract or partnership, it is a material regulatory milestone with operational implications.","company_name":"DR REDDYS LABORATORIES LTD","ticker":"RDY","filing_date":"2026-07-29","form":"6-K","submitted_at":null,"items":[{"id":21196,"accession_number":"0001575872-26-000538","item_number":"EX-99.1","item_title":"rdy0932_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Dr. Reddy's discloses completion of a USFDA Pre-Approval Inspection (PAI) and GMP inspection at its FTO-SEZ Process Unit-02 in Srikakulam, with issuance of a Form 483 containing three observations. This is a regulatory inspection outcome at a manufacturing facility that would affect investor assessment of the company's regulatory compliance status and ability to obtain or maintain FDA approvals for products manufactured at this unit. While not a discrete operational event like a contract or partnership, it is a material regulatory milestone with operational implications.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-29T18:01:39.325269+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":21196,"accession_number":"0001575872-26-000538","item_number":"EX-99.1","item_title":"rdy0932_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Dr. Reddy's discloses completion of a USFDA Pre-Approval Inspection (PAI) and GMP inspection at its FTO-SEZ Process Unit-02 in Srikakulam, with issuance of a Form 483 containing three observations. This is a regulatory inspection outcome at a manufacturing facility that would affect investor assessment of the company's regulatory compliance status and ability to obtain or maintain FDA approvals for products manufactured at this unit. While not a discrete operational event like a contract or partnership, it is a material regulatory milestone with operational implications.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-29T18:01:39.325269+00:00","company_name":"DR REDDYS LABORATORIES LTD","ticker":"RDY","filing_date":"2026-07-29"}]}